Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SFT-005
- Development stage
- Preclinical
- Lead developer
- invoX Pharma
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
SFT-005 is an investigational inhaled drug candidate being developed by invoX Pharma for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The therapy is formulated for delivery via the proprietary Softhaler® platform, which is a dry powder inhaler (DPI) technology designed to optimize drug deposition in the lungs and ensure consistent dosing. As of early 2024, SFT-005 is in the early stages of development (preclinical), and the specific active pharmaceutical ingredient (API) and its molecular mechanism of action have not been publicly disclosed by the developer.
- Other names
- SFT-005-IVOXSFT005-IVOXSFT 005-IVOX
Beyond the preview
Go deeper on SFT-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SFT-005.